Xanthine oxidase-IN-18 is a potent orally bioavailable xanthine oxidase (XO) inhibitor with an IC50 of 0.263 μM. It exerts its inhibitory effects by directly and stably binding to the Mo-co active site of xanthine oxidase. Xanthine oxidase-IN-18 also possesses reactive oxygen species (ROS) scavenging capabilities. In a potassium oxonate-induced hyperuricemia rat model, it exhibits antihyperuricemic effects. This compound is applicable in research related to hyperuricemia, breast cancer, and lung cancer.

Xanthine oxidase-IN-18 (MT7) exhibits no cytotoxicity towards L929 mouse fibroblast cells at concentrations up to 100 μM. It shows approximately twice the inhibitory effect on the growth of MDA-MB-231 breast cancer cells (IC₅₀ = 1.24 μM) compared to A549 lung cancer cells (IC₅₀ = 3.04 μM), confirming its inhibition of intracellular xanthine oxidase (XO). This compound also demonstrates significant concentration-dependent reactive oxygen species (ROS) scavenging activity in RAW 264.7 macrophages at 1-10 μM over 24 hours. After 48 hours, Xanthine oxidase-IN-18 inhibits superoxide dismutase (SOD) by 66%, glutathione reductase (GR) by 49%, and catalase by 38%.

Xanthine oxidase-IN-18, administered at doses of 10, 20, and 40 mg/kg via oral gavage, reduces serum uric acid in a dose-dependent manner in rats with hyperuricemia induced by Potassium oxonate. In an acute oral toxicity study in SD rats, single doses of 5, 50, and 300 mg/kg of Xanthine oxidase-IN-18 showed no mortality or observed toxicity.